Business Context and Reporting Period
Company: Kimberly-Clark Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2007
Business Overview: The Corporation operates four global business segments: Personal Care, Consumer Tissue, K-C Professional & Other, and Health Care. The company is executing a multi-year strategic cost reduction plan aimed at streamlining operations and investing in growth opportunities.
Key Financial Metrics
| Metric (Millions, except per share) | Q3 2007 | Q3 2006 | 9M 2007 | 9M 2006 |
|---|---|---|---|---|
| Net Sales | $4,620.6 | $4,210.4 | $13,507.9 | $12,439.7 |
| Gross Profit | $1,443.5 | $1,275.5 | $4,241.8 | $3,716.2 |
| Operating Profit | $682.7 | $526.4 | $1,947.5 | $1,490.9 |
| Net Income | $453.1 | $364.2 | $1,366.9 | $1,016.9 |
| Diluted EPS | $1.04 | $0.79 | $3.03 | $2.21 |
| Cash from Operations (9M) | $1,743.6 | $1,766.5 | ||
| Cash and Equivalents (End of Period) | $539.6 | $360.8 (Dec 31, 2006) | ||
| Total Debt (Short + Long Term) | $5,775.2 | $3,602.4 (Dec 31, 2006) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 9.7% in Q3 and 8.6% for the nine months ended September 30, 2007. Growth was driven by volume increases (approx. 5% in Q3), improved net selling prices, and favorable foreign currency effects (approx. 3%).
- Profitability: Operating profit rose 29.7% in Q3 and 30.6% for the nine-month period. A primary driver was a significant reduction in strategic cost reduction charges ($100 million lower in Q3 2007 vs. 2006; $340 million lower for the nine months).
- Segment Performance:
- Personal Care: Sales up 12.0% (Q3) and 10.8% (9M); Operating profit up 19.5% (Q3) and 18.4% (9M).
- Consumer Tissue: Sales up 10.5% (Q3); Operating profit declined 7.8% (Q3) due to raw material inflation and higher marketing costs.
- Health Care: Sales down 5.2% (Q3) due to the exit from the latex exam glove business and lower face mask sales compared to the prior year.
- Cost Inflation: Raw material costs increased approximately $70 million in Q3, driven by higher fiber and nonwoven costs, partially offset by cost savings initiatives.
Guidance, Outlook, and Risks
- Strategic Cost Reductions: The company expects cumulative pretax charges of $875 million to $925 million by the end of 2008. The plan targets annual pretax savings of at least $350 million in 2009. Full-year 2007 pretax charges are expected to total approximately $120 million.
- Capital Allocation: The company reaffirmed its commitment to repurchase $2.8 billion of common stock in 2007. In Q3, it executed an Accelerated Share Repurchase (ASR) of $2 billion and repurchased additional shares in the open market. Capital spending for 2007 is expected to be at the high end of the $900 million to $1 billion range.
- Outlook: Management expects top-line momentum to remain positive, driven by developing and emerging markets and targeted growth in Personal Care and K-C Professional. The company anticipates overcoming inflationary pressures through cost reduction efforts.
- Risks and Contingencies:
- Tax Uncertainty: Adoption of FIN 48 resulted in a $34.2 million decrease in retained earnings. Approximately $490 million of unrecognized tax benefits remain, with transfer pricing being the most significant uncertainty.
- Raw Materials: Fluctuations in the prices of fiber, pulp, and oil-based materials pose a risk to margins.
- Health Care Transition: Sales of exam gloves declined over 20% in Q3 as the company transitions customers from latex to nitrile gloves; supply constraints and competitive conditions remain risks.
Investor Verification Checklist
- Debt Levels: Verify the impact of the $2 billion ASR financing on interest expense and leverage ratios, as total debt increased by approximately $2.2 billion year-over-year.
- Health Care Segment: Monitor the transition from latex to nitrile gloves to ensure sales growth compensates for the volume decline in the latex category.
- Cost Savings Realization: Track the realization of the targeted $350 million annual pretax savings from the strategic cost reduction plan against ongoing raw material inflation.
- Tax Liabilities: Review the status of the $490 million in unrecognized tax benefits and potential settlements related to transfer pricing.
- Share Count: Confirm the dilutive impact of the accelerated share repurchase program on future earnings per share calculations.